Azura Ophthalmics Overview
Azura Ophthalmics is utilizing a deep understanding of ocular surface diseases and drug development to deliver a new therapeutic class of ophthalmic keratolytics to treat underserved ophthalmic conditions. Azura has a robust clinical-stage program focused on resolving the pathophysiology of meibomian gland dysfunction and contact lens discomfort. It is Azura's belief that AZR-MD-001 can reverse the core pathophysiology of these conditions, alleviating their signs and symptoms. Additional areas of focus include the development of the company's novel new chemical entities, which target the pathophysiology of ocular surface diseases with a multi-modal mechanism of action.
Cumulative Funding Raised Over Time ($)
$1.2MMar 2014
$17.2MOct 2017
$37.2MOct 2020
Latest News
Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U.S. and European Patents
Azura Ophthalmics Provides Update on AZR-MD-001 Phase 2 Clinical Program Targeting Meibomian Gland Dysfunction
Azura Ophthalmics Announces Formation of Scientific Advisory Board (SAB)
Azura Ophthalmics Secures Grant to Evaluate AZR-MD-001 for Improved Vision Quality Related to Contact Lens Discomfort
growth-positive
Azura Ophthalmics Announces Positive Topline Results From Phase 2 Program of the Company's Investigational Treatment for Meibomian Gland Dysfunction
Azura Ophthalmics Ltd. has announced positive results from a phase 2 program evaluating its investigational therapy for Meibomian gland dysfunction (MGD). The therapy, AZR-MD-001, met its primary endpoints showing improvements in signs and symptoms of MGD. MGD is a chronic condition where the glands that line the eyelids become blocked, preventing them from secreting enough oil into the tear film needed to properly lubricate the eye. It is the main cause of Dry Eye Disease (DED). Azuras therapy is designed to restore Meibomian gland function by addressing the abnormal hyperkeratinization that blocks the glands.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $37.2M |
| Last funding | Undisclosed |
| Stage | C |
| Rounds | 4 |
| Investors | 4 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | azuraophthalmics.com/ |
| Careers | Careers page |
Locations
Druyanov St 5, Tel Aviv-Yafo, Israel
Photos & Videos
1 item(s)
Azura Ophthalmics Business
Business models
B2B
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnologyCore Technology
BiologicalsTags (6)
medicationdrug-discoveryophthalmologychronic-patientsbiotechnologyeye-diseasesGeographic Markets
GlobalAzura Ophthalmics Financials
$37.2M
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
C
Funding stage
4
Total rounds
4
Investors
Cumulative Funding Raised Over Time ($)
$1.2MMar 2014
$17.2MOct 2017
$37.2MOct 2020
Private Equity Funding
C Round
Oct 2020
$20M
OrbiMed (Lead)
,
Ganot Capital, TPG Biotech, Brandon Capitals Medical Research Commercialization Fund
B Round
Oct 2017
$16M
Brandon Capitals Medical Research Commercialization Fund, OrbiMed, TPG Biotech, Ganot Capital
A Round
Mar 2014
$1.2M
Non-Equity Funding
GrantEvent
Sep 2022
Undisclosed
CUREator (Lead)
Azura Ophthalmics Lifecycle
Cumulative Funding Raised Over Time
$1.2MMar 2014
$17.2MOct 2017
$37.2MOct 2020
All Events
C Round
Oct 2020
$20M
OrbiMed (Lead)
,
Ganot Capital, TPG Biotech, Brandon Capitals Medical Research Commercialization Fund
B Round
Oct 2017
$16M
Brandon Capitals Medical Research Commercialization Fund, OrbiMed, TPG Biotech, Ganot Capital
A Round
Mar 2014
$1.2M
GrantEvent
Sep 2022
Undisclosed
CUREator (Lead)
Azura Ophthalmics News
9 articlesAzura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U.S. and European Patents
Azura Ophthalmics Provides Update on AZR-MD-001 Phase 2 Clinical Program Targeting Meibomian Gland Dysfunction
Azura Ophthalmics Announces Formation of Scientific Advisory Board (SAB)
Azura Ophthalmics Secures Grant to Evaluate AZR-MD-001 for Improved Vision Quality Related to Contact Lens Discomfort
growth-positive
Azura Ophthalmics Announces Positive Topline Results From Phase 2 Program of the Company's Investigational Treatment for Meibomian Gland Dysfunction
Azura Ophthalmics Ltd. has announced positive results from a phase 2 program evaluating its investigational therapy for Meibomian gland dysfunction (MGD). The therapy, AZR-MD-001, met its primary endpoints showing improvements in signs and symptoms of MGD. MGD is a chronic condition where the glands that line the eyelids become blocked, preventing them from secreting enough oil into the tear film needed to properly lubricate the eye. It is the main cause of Dry Eye Disease (DED). Azuras therapy is designed to restore Meibomian gland function by addressing the abnormal hyperkeratinization that blocks the glands.
Investment
Azura Ophthalmics Announces Primary Endpoints Met in Topline Results from Phase 2 Trial of the Company's Investigational Treatment for Contact Lens Discomfort
growth-positive
Eyeing pandemic's silver lining for drug trials
Azura Ophthalmics, a biotechnology company, has raised $28 million in funding for its ointment to prevent dry eye. The company, which has raised a total of $53 million, is focused on developing a compound to address Meibomian gland dysfunction, a cause of dry eye. The compound uses the active ingredient selenium disulfide, which is found in anti-dandruff shampoo Selsun Blue. Azura has created a safe method for applying the compound to the eyelids. The company aims to file for approval with the US Food and Drug Administration by the end of 2023. The recent funding round demonstrates confidence in the data from the companys tests.
Investment
growth-positive
Azura Ophthalmics gets a $20M boost for its R&D work on eye diseases
Azura Ophthalmics, a biotech company based in Tel Aviv-Yafo, Israel, has raised $20 million in funding from a group of investors. This brings their total fundraising amount to $38 million. The funding will support a registration study of their lead candidate, AZR-MD-001, which is designed to address Meibomian gland dysfunction and related eye diseases, including dry eye disease.
Investment
Azura Ophthalmics Receives $16 Million in Series B Funding to Develop Treatment for Leading Cause of Dry Eye Disease
Azura Ophthalmics Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 14 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
Azura Ophthalmics Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | markets, not claimed |
| BI Verification | Jenny Sotnik-Talisman |
| Registrar ID | 515003747 |
| Crunchbase | azura-ophthalmics |
| Phone | +97236475312 |
| Creator | Jenny Sotnik-Talisman |
| Creator email | genys30@yahoo.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-11-01T00:00:00.000Z |
| Created | 2017-10-10T00:00:00.000Z |